sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Arsenic trioxide

Medicine

Arsenic trioxide

Arsenic trioxide injection is an arsenical

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • In combination with tretinoin
  • for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. Newly-Diagnosed Low-Risk APL Arsenic trioxide injection is indicated
  • in combination with tretinoin
Do not take if
TRISENOX is contraindicated in patients with hypersensitivity to arsenic.

What it is used for

Arsenic trioxide injection is an arsenical indicated: In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Newly-Diagnosed Low-Risk APL Arsenic trioxide injection is indicated in combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. Relapsed or Refractory APL Arsenic trioxide injection is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Differentiation Syndrome
  • Cardiac Conduction Abnormalities
  • Encephalopathy
  • Hepatotoxicity
  • Carcinogenesis

Who should not take it

TRISENOX is contraindicated in patients with hypersensitivity to arsenic.

Other medicines and interactions

Drugs That Can Prolong the QT/QTc Interval

Concomitant use of these drugs and TRISENOX may increase the risk of serious QT/QTc interval prolongation. Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while the patient is using TRISENOX. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use.

Drugs That Can Lead to Electrolyte Abnormalities

Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation. Avoid concomitant use of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and TRISENOX.

Drugs That Can Lead to Hepatotoxicity

Concomitant use of these drugs and TRISENOX, particularly when given in combination with tretinoin, may increase the risk of serious hepatotoxicity. Discontinue or replace with an alternative drug that does not cause hepatotoxicity while the patient is using TRISENOX. Monitor liver function tests more frequently in patients when it is not feasible to avoid concomitant use.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Arsenic trioxide; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/arsenic-trioxide

APA 7th

sofidex. (2026, August 3). Arsenic trioxide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/arsenic-trioxide

AMA 11th

Arsenic trioxide. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/arsenic-trioxide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.